Expert Interview
Discussing the P1 data presented at ESMO for ubamatamab, a CD3-targeting bispecific antibody under investigation for recurrent ovarian cancer
Ticker(s): REGNInstitution: UCLA School of Medicine
- Community based hematologist and oncologist
- treats 25 patients with with relapsed or refractory acute myeloid leukemia
- familiar with some of the results from the pivotal Phase 3 SIERRA Trial of Iomab-B
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
